Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked.
The question about glucagon receptor agonist that I actually want answered is the second one below. The first is context and I have kept it short.
Both are stated with units, and I have said what I already checked so that nobody repeats it.
The opening post put the caveat in the right place and I want to underline it.
Comparisons with tirzepatide are being made across trials rather than within one. Different populations, different durations, different endpoints; the effect sizes are not commensurable and nobody has run the head-to-head.
No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.
Taking post #4 at face value and following it one step further.
Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.
Grateful for the specificity. Vague answers to this question are what sent me looking.
On identity confirmation more generally: for a compound with no widely available reference material, orthogonal confirmation matters more than usual. A mass result and a chromatographic result together say considerably more than either alone.
Happy to be corrected if someone holds better data than mine.
Glycaemic effects improved rather than worsened in the diabetes work despite the glucagon component, which is the observation that resolves the apparent paradox. It is worth understanding that mechanism before repeating either half of it.
That is the practical version. The rigorous version is longer and says the same thing.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Retatrutide's phase 2 heart-rate signal and how to think about it
On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. Putting the numbers in the first post, because a question about a…
|
+19 | 23 | 20k | 7mo |
|
What we do not know about retatrutide, listed explicitly
The question in the title: What we do not know about retatrutide, listed explicitly I will give what I have already checked below so nobody repeats it. Setting out what I think I know about this compound and…
|
+106 | 113 | 4.8k | 17mo |
|
Hepatic effects of glucagon receptor agonism: the mechanistic worry
Posting this under the heading it deserves: Hepatic effects of glucagon receptor agonism: the mechanistic worry Everything below is what sits behind that. Something about hepatic effects of glucagon receptor…
|
+51 | 56 | 700 | 22mo |
|
Retatrutide mass and identity: what a report should show
Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that. The question about retatrutide mass and identity that I actually…
|
+22 | 27 | 872 | 22h |
|
Second pass at: Triple agonism: additive, synergistic, or neither?
Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a small dataset on Triple agonism. It is…
|
+114 | 120 | 1.4k | 10mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on receptor…
|
+52 | 57 | 25k | just now |
|
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first…
|
2 | 39k | 6mo | |
|
[2026 update] Correlation in a self-tracked dataset: what it can support
Posting this under the heading it deserves: Correlation in a self-tracked dataset: what it can support Everything below is what sits behind that. Posting a small dataset on Correlation. It is mine, it is…
|
2 | 31k | 6h | |
|
Reading a combination trial: attributing effect to components
On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Collecting what is known about reading a combination trial in one place,…
|
4 | 19k | 11mo | |
|
Retatrutide mass and identity: what a report should show
Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that. The question about retatrutide mass and identity that I actually…
|
+22 | 27 | 872 | 22h |